Peng Jun, Shao Na, Peng Hongling, Chen Long-Qi
West China Medical School, Sichuan University, Chengdu, Sichuan, China.
J BUON. 2013 Apr-Jun;18(2):398-406.
The purpose of this study was to comprehensively and quantitatively review eligible published studies to explore the prognostic significance of vascular endothelial growth factor (VEGF) expression in patients with esophageal carcinoma (EC).
PubMed and Embase databases were searched until September 11, 2011. A meta-analysis was performed to demonstrate any relationship between VEGF and 5-year overall survival (OS) in EC patients.
The final analysis included 1453 patients from 19 studies. The studies were grouped by patient source, histology, VEGF isoform and cutoff value. The estimated risk of death suggested that VEGF positivity had negative impact on prognosis of patients with EC, esophageal squamous cell carcinoma (ESCC) and Asian patients. The risk ratios (RR) and 95% confidence interval (95% CI) were 1.26 (1.16-1.37) in EC patients, 1.28 (1.16-1.40) in ESCC patients and 1.35 (1.24-1.48) in Asian patients. Furthermore, when the cutoff value was set at 10% in 6 studies, the RR (95% CI) was 1.48 in the VEGF positive group (1.27-1.73). In addition, VEGFC was also correlated with patient poor prognosis with a RR (95% CI) of 1.30 (1.15-1.48). However, EC patients from non-Asian countries and cutoff value at 30% showed no significant correlation with survival. Data were not sufficient to determine the prognostic value of VEGF expression in esophageal adenocarcinoma (EA) patients and VEGFD expression.
VEGF positivity indicated poor prognosis in patients with EC, ESCC and of Asian origin. Cutoff value at 10% may be a more appropriate standard to define VEGF positivity. VEGFC also correlated with poor prognosis in EC patients.
本研究旨在全面且定量地回顾符合条件的已发表研究，以探讨血管内皮生长因子（VEGF）表达在食管癌（EC）患者中的预后意义。
检索PubMed和Embase数据库直至2011年9月11日。进行荟萃分析以证明EC患者中VEGF与5年总生存率（OS）之间的任何关系。
最终分析纳入了来自19项研究的1453例患者。这些研究按患者来源、组织学、VEGF亚型和临界值进行分组。估计的死亡风险表明，VEGF阳性对EC患者、食管鳞状细胞癌（ESCC）患者和亚洲患者的预后有负面影响。EC患者的风险比（RR）和95%置信区间（95%CI）为1.26（1.16 - 1.37），ESCC患者为1.28（1.16 - 1.40），亚洲患者为1.35（1.24 - 1.48）。此外，在6项研究中将临界值设定为10%时，VEGF阳性组的RR（95%CI）为1.48（1.27 - 1.73）。另外，VEGFC也与患者预后不良相关，RR（95%CI）为1.30（1.15 - 1.48）。然而，来自非亚洲国家的EC患者以及临界值为30%时与生存率无显著相关性。数据不足以确定VEGF表达在食管腺癌（EA）患者和VEGFD表达中的预后价值。
VEGF阳性表明EC患者、ESCC患者及亚洲裔患者预后不良。10%的临界值可能是定义VEGF阳性的更合适标准。VEGFC也与EC患者预后不良相关。
